What is the latest HCG stock price?
The latest stored price for HCG is Rs 725.95 as of 2026-08-21.
gimli
HCG stock AI analysis
HCG Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
HEALTHCARE GLOB. ENT. LTD is a small-cap stock in Healthcare. This Gimli page shows the latest available HCG price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹725.95
1W return
+1.63%
1M return
+9.78%
3M return
+15.78%
6M return
+23.34%
1Y return
+7.06%
Market cap
₹10,838.59 cr
PE
742.88
PB
7.69
ROE
+1.22%
ROCE
+7.07%
RSI
61.68
Turnover
₹6.99 cr
Why it can matter in screens
- Momentum: HCG is above 50DMA, above 200DMA; RSI is 61.68.
- Returns: 1D -0.62%, 1W +1.63%, 1M +9.78%, 3M +15.78%, 1Y +7.06%.
- Trend levels: 52W high ₹755.00, 52W low ₹590.60, off high -3.85%.
- Liquidity: latest turnover is ₹6.99 cr; volume vs 20D is +0.51%.
- Valuation/profitability: PE 742.88, PB 7.69, ROE +1.22%, ROCE +7.07%.
- Growth: 3Y sales CAGR +14.84%, 3Y profit CAGR -22.31%.
Quick Answers
Is HCG above its 50DMA and 200DMA?
HCG is above 50DMA, above 200DMA. The latest 50DMA is 664.58 and the latest 200DMA is 640.17.
What are HCG PE, ROE and ROCE?
HCG has PE 742.88, ROE +1.22%, and ROCE +7.07% in Gimli's latest available snapshot.
How has HCG performed recently?
HCG has returned +9.78% over 1 month, +15.78% over 3 months, and +7.06% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 386.22 cr | 68.78 cr | 5.58 cr | 0.92 |
| 2026-03-31 | 650.29 cr | 106.76 cr | 2.17 cr | 0.15 |
| 2025-12-31 | 631.18 cr | 99.36 cr | -9.43 cr | -0.68 |
| 2025-09-30 | 645.16 cr | 126.24 cr | 16.27 cr | 1.15 |
| 2025-06-30 | 611.80 cr | 115.30 cr | 4.75 cr | 0.34 |
| 2025-03-31 | 583.43 cr | 115.86 cr | 7.36 cr | 0.52 |
| 2024-12-31 | 557.55 cr | 93.92 cr | 6.98 cr | 0.50 |
| 2024-09-30 | 552.47 cr | 113.37 cr | n/a | 1.28 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 2,538.43 cr | 447.66 cr | 13.76 cr | 0.97 |
| 2025-03-31 | 2,218.14 cr | 422.86 cr | 44.41 cr | 3.17 |
| 2024-03-31 | 1,889.91 cr | 342.78 cr | 48.16 cr | 3.44 |
| 2023-03-31 | 1,676.05 cr | 302.75 cr | 29.35 cr | 2.10 |
| 2022-03-31 | 862.25 cr | 332.83 cr | 38.25 cr | 2.83 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 3,922.54 cr | 536.05 cr | 1,735.36 cr | 1,410.21 cr |
| 2025-03-31 | 3,543.24 cr | 235.87 cr | 1,837.22 cr | 990.05 cr |
| 2024-03-31 | 2,707.50 cr | 272.61 cr | 1,274.36 cr | 865.12 cr |
| 2023-03-31 | 2,316.02 cr | 174.62 cr | 901.20 cr | 869.42 cr |
| 2022-03-31 | 2,219.52 cr | 197.51 cr | 914.68 cr | 883.71 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 347.10 cr | 55.00 cr | n/a |
| 2025-03-31 | 317.11 cr | 108.24 cr | n/a |
| 2024-03-31 | 284.58 cr | 98.90 cr | n/a |
| 2023-03-31 | 251.59 cr | 118.35 cr | n/a |
| 2022-03-31 | 220.12 cr | 148.89 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +64.21% | +2.74% | +19.20% | +15.43% | +13.85% | +5.17% |
| 2026-03-31 | +64.21% | +2.75% | +18.91% | +15.31% | +14.13% | +5.17% |
| 2026-03-27 | +64.21% | +2.71% | +18.89% | +15.31% | +14.18% | +5.17% |
| 2025-12-31 | +63.77% | +3.22% | +18.30% | +15.08% | +14.71% | +5.52% |
| 2025-09-30 | +63.78% | +3.59% | +18.36% | +14.63% | +14.27% | +5.52% |
| 2025-06-30 | +62.46% | +2.16% | +13.22% | +9.43% | +22.16% | +5.70% |
| 2025-03-31 | +71.22% | +2.45% | +12.47% | +9.19% | +13.86% | +4.99% |
| 2024-12-31 | +71.23% | +2.77% | +12.94% | +10.04% | +13.06% | +3.09% |
| 2024-09-30 | +71.23% | +4.29% | +11.64% | +8.94% | +12.83% | +3.09% |
| 2024-06-30 | +71.25% | +3.95% | +10.89% | +8.73% | +13.90% | +3.09% |
| 2024-03-31 | +71.28% | +6.74% | +8.52% | +6.49% | +13.46% | +3.09% |
| 2023-12-31 | +71.29% | +6.36% | +8.46% | +6.38% | +13.89% | +3.09% |
| 2023-09-30 | +71.30% | +6.28% | +7.94% | +5.67% | +14.48% | +3.09% |
| 2023-06-30 | +71.35% | +6.47% | +6.58% | +4.56% | +15.59% | +3.09% |
| 2023-03-31 | +71.37% | +6.37% | +5.54% | +3.87% | +16.72% | +3.09% |
| 2022-12-31 | +71.38% | +7.17% | +4.40% | +3.01% | +17.04% | +3.09% |
| 2022-09-30 | +71.39% | +7.27% | +4.03% | +2.81% | +17.31% | +3.09% |
| 2022-06-30 | +71.42% | +0.00% | +11.77% | n/a | n/a | +3.00% |
| 2022-03-31 | +71.43% | +0.00% | +12.85% | n/a | n/a | +3.00% |
| 2021-12-31 | +71.44% | +0.00% | +13.62% | n/a | n/a | +3.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 456,449.49 cr | 37.677543 | +15.50% | +15.99% |
| DIVISLAB | DIVI S LABORATORIES LTD | 228,223.36 cr | 78.319614 | +18.37% | +42.62% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 165,719.79 cr | 75.983398 | +17.33% | +34.25% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 124,992.04 cr | 63.823550 | +21.03% | +9.67% |
| CIPLA | CIPLA LTD | 115,693.19 cr | 34.304976 | +10.25% | -10.08% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,698.21 cr | 22.474914 | +17.93% | +13.61% |
| LUPIN | LUPIN LIMITED | 100,669.80 cr | 14.727517 | +34.34% | +12.19% |
| MANKIND | MANKIND PHARMA LIMITED | 98,418.27 cr | 47.977550 | +13.18% | -8.31% |
Try these prompts
- Analyze HEALTHCARE GLOB. ENT. with valuation, momentum and industry peers
- Compare HCG with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare HCG with other Healthcare stocks
Data snapshot: 2026-08-21. Not investment advice.